Newsletter | February 3, 2026

02.03.26 -- CROs In Early Drug Discovery, Part 3: Budgets, Timelines, And Avoiding Pitfalls

SPONSOR

BioPlan Associates is conducting its 23rd Annual Global Biopharmaceutical Manufacturing and Trends Analysis and needs your insights for the biopharma industry’s most comprehensive global benchmarking analysis! For over 20 years, BioPlan Associates has analyzed advances in bioprocessing, new technologies, and emerging trends, supported by global institutional and media partners. For all completed, qualified surveys, they'll offer an Amazon e-gift card, a copy of the summary results, and the 2026 Top Trends in Biomanufacturing White Paper.

FROM THE EDITOR

Insights From The Non-Opioid Pain Therapeutics Summit: Human-Centric Translational Models And The Reawakening Of Pain Pipelines

By Ray Dogum, chief editor, Drug Discovery Online

The 2026 Inaugural Non-Opioid Pain Therapeutics Summit brought together a diverse group of scientists, clinicians, and drug hunters to discuss developing safe, effective pain medicines without the addictive properties associated with opioids.

FEATURED EDITORIAL

CROs In Early Drug Discovery, Part 3: Budgets, Timelines, And Avoiding Pitfalls

By Simon Cocklin and Chan Soon-Shiong, Institute for Molecular Medicine at Windber

Part 3 of this series covers managing budgets, timelines, and avoiding operational pitfalls.

Is Oncology Precision Medicine Coming of Age?

By Thomas Pataillot-Meakin, Ph.D., Laura Knighton, Ph.D., and Kasia Koczula, Ph.D., Lifescience Dynamics

Developers are releasing new data suggesting that their targeted therapy candidates may finally address some of oncology’s toughest challenges.

INDUSTRY INSIGHTS

Unlocking miRNA Biomarkers With NGS And Digital PCR

Webinar | QIAGEN

Discover how next-generation sequencing and digital PCR enable miRNA biomarker discovery and validation, as well as best practices for sample prep and assay design to advance RNA research.

Powering Drug Development With Advanced AI Retrosynthetic Analysis Tools

Article | Lonza

Review advanced retrosynthetic analysis services and how these tools empower better, more efficient development of innovative small molecule drugs.

Using A Colon Intestine-Chip To Study GI Disease Mechanisms

Webinar | Emulate

What are the applications and benefits of Organ-Chips, and what makes them superior to organoids in the study of gastrointestinal-related diseases?

Extractables And Leachables: Risk Management And Analytical Solutions

White Paper | By Matthew St. Lawrence, Todd Sprouse, and Erik Feldmann, Ph.D., Cambrex

Partnering with a CDMO that offers comprehensive and robust E&L studies can help facilitate a smooth product launch by ensuring minimal impact from impurities, all while mitigating risks.

Crystallization Of Challenging Pharmaceutical Targets To Aid Drug Discovery

Article | By Mary Koszelak-Rosenblum, Ph.D. and Guangyu Zhu, Ph.D., Curia

Examine a few successful strategies used when growing crystals of challenging pharmaceutical targets to aid drug discovery, and two case studies performed by an experienced team of crystallographers.

Rapid, Material-Sparing Feasibility Screening For Hot Melt Extrusion

Webinar | Lonza

Explore a screening process to quickly assess HME feasibility that yields more accurate predictions for API loading and degradation while saving material and time compared to traditional approaches.

SOLUTIONS

Solid Form Services

Lonza

The Role Of High-Quality Anti-Host Cell Protein Antibody Reagents

Labcorp Drug Discovery Solutions

Immunoassays For Cytokine And Chemokine Quantitation

BD Biosciences